Zhejiang Tasln Biopharma Co.,Ltd
We are professional supplier of Semaglutide,Tirzepatide,Retatrutide,GHK-CU,Linaclotide,Cagrilintide,Eptifibatide.
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
Product Description
Survodutide (BI 456906) is a novel dual agonist of glucagon (GCG) and GLP-1 receptors. It is a synthetic 29-amino acid peptide engineered from the GLP-1 backbone, designed for once-weekly subcutaneous administration. The dual mechanism combines GLP-1-mediated appetite suppression with GCG-mediated energy expenditure increase, offering synergistic effects on weight reduction and metabolic control.
Key Features:
Dual GCG/GLP-1 receptor agonist
Once-weekly administration
Phase 3 clinical-stage asset
Promotes appetite suppression and energy expenditure
Direct liver fat reduction for MASH research
Clinical Data:
Phase 3 (SYNCHRONIZE-1): Up to 16.6% weight loss at 76 weeks (obesity without diabetes)
85.1% of participants achieved ≥5% weight reduction
Significant liver fat reduction observed
Specifications:
| Parameter | Specification |
|---|---|
| Appearance | White to off-white lyophilized powder |
| Purity (HPLC) | ≥98% (≥99% available) |
| CAS No. | 1453870-71-1 |
| Molecular Formula | C₁₈₉H₂₉₂N₄₀O₆₁ |
| Molecular Weight | ~3,990 g/mol |
| Storage | -20°C, dry, protected from light |
| Shelf Life | 24 months |
| GMP Compliance | cGMP standards |
Applications:
Obesity and overweight research
Type 2 diabetes studies
Metabolic-associated steatohepatitis (MASH/NASH) research
Metabolic syndrome studies
Preclinical and clinical trial supply
Documentation Available:
Certificate of Analysis (COA)
Stability study data (24 months)
GMP statement
DMF filing support
Packaging & Shipping:
Packaging: Sealed pharmaceutical-grade vials
Storage: -20°C, dry, protected from light
Shipping: Temperature-controlled (blue ice/dry ice)
